BIONTECH SE ADR
BIONTECH SE ADR
Share · US09075V1026 · BNTX · A2PSR2 (XFRA)
Overview Financial Indicators
95,21 EUR
-0,56 % -0,54 EUR
Closing Price XFRA 06.06.2025: 96,45 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 22:29

Current Prices from BIONTECH SE ADR

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
BNTX
USD
06.06.2025 22:29
108,54 USD
110,15 USD
-1,46 %
XFRA: Frankfurt
Frankfurt
22UA.F
EUR
06.06.2025 17:13
96,45 EUR
97,75 EUR
-1,33 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 12,96 % 13,69 % -6,90 % -17,32 % 1,06 % 118,66 %

Company Profile for BIONTECH SE ADR Share

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Invested Funds

The following funds have invested in: BIONTECH SE ADR invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
862,43
Percentage (%)
2,02 %

Company Data

Name BIONTECH SE ADR
Company BioNTech SE
Symbol BNTX
Website https://www.biontech.de
Primary Exchange XFRA Frankfurt
WKN A2PSR2
ISIN US09075V1026
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Ugur Sahin M.D.
Market Capitalization 21 Mrd.
Country Germany
Currency EUR
Employees 6,8 T
Address An der Goldgrube 12, 55131 Mainz
IPO Date 2019-10-11

Ticker Symbols

Name Symbol
Frankfurt 22UA.F
NASDAQ BNTX
XETRA 22UA.DE

More Shares

Investors who BIONTECH SE ADR hold also have the following shares in their portfolio:
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Share
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Share
AMAZON.CO INC
AMAZON.CO INC Share
APPLE INC
APPLE INC Share
DZ BANK      IS.A2708
DZ BANK IS.A2708 Bond
Intapp, Inc. - Common Stock
Intapp, Inc. - Common Stock Share
META PLATFORMS INC
META PLATFORMS INC Share
MICROSOFT CORP
MICROSOFT CORP Share
NVIDIA CORP
NVIDIA CORP Share
PAYPAL INC
PAYPAL INC Share
PROCREDIT   ANL.20/25
PROCREDIT ANL.20/25 Bond
SIEMENS GLOBAL GROWTH A
SIEMENS GLOBAL GROWTH A Fund
SQUARE INC A
SQUARE INC A Share
TESLA INC
TESLA INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025